Correlation between the Inflammation Factors and Intima-Media Thickness in Patients with End-Stage Renal Disease (ESRD) on Regular Hemodialysis

Lestariningsih Lestaringsih, Wiguno Projosudjadi, Mochamad Sya’bani, Suharyo Hadisaputro


Background: Several emerging problems of regular hemodialysis (HD) including cardiovascular complication or atherosclerosis formation caused by chronic inflammation. High sensitive C-reactive protein (hs-CRP) and intima-media thickness (IMT) of the carotid artery can be applied as atherosclerosis progressivity marker. This study was designed to investigate the relationship between some inflammatory factors, including hs-CRP, interleukin (IL)-6, oxidized-low-density lipoproteins (LDL), with  IMT  among end-stage renal disease (ESRD) patients. This was the first study in Indonesian population. 

Materials and Methods: This cross-sectional study was performed on ESRD patients who performed regular HD at Hemodialysis Unit of Dr. Kariadi Hospital and Telogorejo Hospital Semarang between October 2009 and April 2010. This was a preliminary report for the cohort study.

Results: Seventy-eight HD subjects were enrolled in this study, with mean age of 49.8 years old. Mean HD duration was 25.5±32.16 months. The mean carotid artery wall thickness was 0.64±0.149 mm. IL-6, hs-CRP, and ox-LDL level were higher in IMT group ≥0.5 mm than IMT group <0.5 mm. There was a significant correlation between hs-CRP (prevalence ratio (PR)=1.3; 95% confidence interval (CI)=1.02-1.7; p-value=0.01) as well as IL-6 (PR=1.5; 95% CI=1.1 -2.0; p-value<0.001) and IMT wall thickness. The oxidized-LDL level was not a significant factor to be associated with IMT. The cut-off value for hs-CRP and IL-6 to predict IMT progressivity was 2.8 mg/L and 2.88 mg/L, respectively.

Conclusion: There was a significant correlation between IL-6 and hs-CRP levels and IMT. There was not significant correlation between oxidized LDL and IMT.

Keywords: hemodialysis, atherosclerosis, IMT, IL-6, hs-CRP, Oxidized-LDL

Full Text:



Collins AJ, Foley RN, Gilbertson DT, Chen S. United States Renal Data System public health surveillance of chronic kidney disease and end-stage renal disease. Kidney Int Suppl. 2015; 5(1): 2-7, CrossRef.

Stenvinkel P. Inflammation in end-stage renal failure: could it be treated? Nephrol Dial Transpl. 2002; Suppl 8: 33-8, CrossRef.

Bowry S, Kuchienke KU, Ronco C. The cardiovascular burden of the dialysis patient: the impact of dialysis technology. In: Ronco C, Brendolan A, Levin NW, editors. Cardiovascular Disorders in Hemodialysis. Basel: Karger; 2005. p.230-9, CrossRef.

Heidari B. C-reactive protein and other markers of inflammation in hemodialysis patients. Caspian J Intern Med. 2013; 4(1): 611-6, Link.

Park KA, Jo HM, Han JS, Kim MJ, Kwun DH, Park MY, et al. Features of atherosclerosis in hemodialysis patients. Kidney Res. 2013; 32(4): 177-82, CrossRef.

Smook MLF, Leeuwen M van, Heeringa P, Damoiseaux JGMC, Theunissen R, Daemen MJAP, et al. Anti-oxLDL antibody isotype levels, as potential markers for progressive atherosclerosis in APOE−/− and APOE−/−CD40L−/− mice. Clin Exp Immunol. 2008; 154(2): 264-9, CrossRef.

Raghavamenon SPA, Garelnabi MO, Santanam N. Oxidized Low-Density Lipoprotein. Methods Mol Biol. 2010; 610: 403-17, CrossRef.

Taheri S, Baradaran A, Aliakbarian M, Mortazavi M. Level of inflammatory factors in chronic hemodialysis patients with and without cardiovascular disease. J Res Med Sci. 2017; 22: 47, CrossRef.

Santoro A. Cardiac effect of chronic inflammation in dialysis patient. Nephrol Dial Transpl. 2002; 175(8): 10-5, Link.

Szeto C, Chow K, Woo K, Chook P, Ha-Kwan B. Carotid intima media thickness predicts cardiovascular diseases in Chinese pre-dialysis patients with chronic kidney disease. J Am Soc Nephrol. 2007; 18(6): 1966-72, CrossRef.

Touboul P, Hennerici M, Meairs S, Adams H, Amarenco P, Desvarieux M. Mannheim intima-media thickness consensus. Cerebrovasc Dis. 2004; 18(4): 346-9, CrossRef.

Eigenbrodt M, Bursac Z, Couper. Mathematical estimation of the potential effect of vascular remodeling/dilatation on B-mode ultrasound intima-medial thickness. Q J Med. 2004; 97(11): 729-37, CrossRef.

Salonen JT, Salonen R. Ultrasonographically assessed carotid morphology and the risk of coronary heart disease. Arterioscler Thromb. 1991; 11(5): 1245-9, CrossRef.

Liao D, Arnett D, Tyroler H, Riley W, Chambless L, Szklo M, et al. Arterial stiffness and the development of hypertension. The ARIC study. Hypertension. 1999; 34(2): 201-6, CrossRef.

Kaess BM, Larson MG, Hamburg NM, Vita JA, Levy D, Benjamin EJ, et al. Aortic stiffness, blood pressure progression, and incident hypertension and Incident Hypertension. 2012; 308(9): 875-81, CrossRef.

Adolphe A, Cook LS, Huang X. A Cross-sectional study of intima-media thickness, ethnicity, metabolic syndrome, and cardiovascular risk in 2268 study participants. Mayo Clin Proc. 2009; 84(3): 221-8, CrossRef.

Mackinnon A, Dunne P, Sitzer M, Buehler A, Kegler S, Markus H. Rate and determinants of site-specific progression of carotid artery intima-media thickness. Stroke. 2004; 35(9): 2150-4, CrossRef.

Kawamoto R, Tomita H, Inoue A, Ohtsuka N, Kamitani A. Impact of C-reactive protein on the likelihood of carotid atherosclerosis in Japanese adults. J Atheroscler Thromb. 2006; 13(4): 175-82, CrossRef.

Kato A, Odamaki M, Takita T, Maruyama Y, Kumagai H, Hishida A. Association between interleukin-6 and carotid atherosclerosis in hemodialysis patients. Kidney Int. 2002; 61(3): 1143-52, CrossRef.

Ok E, Kircelli F, Asci G, Altunel E, Ertilav M. Neither oxidized nor anti- oxidized low-density lipoprotein level is associated with atherosclerosis or mortality in hemodialysis patients. Hemodial Int. 2012; 16(3): 334-41, CrossRef.

Kasliwal RR, Bansal M, Devang D, Sharma M. Carotid intima-media thickness: current evidence, practices, and Indian experience. Indian J Endocrinol Metab. 2014; 18(1): 13-22, CrossRef.

Piroddi M1, Depunzio I, Calabrese V, Mancuso C, Aisa CM, Binaglia L, et al. Oxidatively-modified and glycated proteins as candidate pro-inflammatory toxins in uremia and dialysis patients. Amino Acids. 2007; 32(4): 573-92, CrossRef.

Kharbanda R, MacAllister R. The atherosclerosis time-line and the role of the endothelium. Curr Med Chem - Immunol Endocr Metab Agents. 2005; 1(1): 47-52, CrossRef.

Stary HC. Natural history and histological classification of atherosclerotic lesions. Arter Thromb Vasc Biol. 2000; 20(5): 1177-8, Link.

Sonoda M, Yonekura K, Yokoyama I, Takenaka K, Nagai R, Aoyagi T. Common carotid intima-media thickness is correlated with myocardial flow reserve in patients with coronary artery disease: a useful non-invasive indicator of coronary atherosclerosis. Int J Cardiol. 2004; 93(2-3): 131-6, CrossRef.

Schwedler, S, Schinzel, R. Vaith, P. Wanner C. Inflammation and advanced glycation end products in uremia: simple coexistence, potentiation or causal relationship? Kidney Int Suppl. 2001; 78: S32-6, CrossRef.

Kalousová, M. Zima, T. Tesar, V. Lachmanová J. Advanced glycation end products and advanced oxidation protein products in hemodialyzed patients. Blood Purif. 2002; 20(6): 531-6, CrossRef.


Copyright (c) 2019 Lestariningsih Lestaringsih

Indexed by:




Cell and BioPharmaceutical Institute